ISRG Quote, Financials, Valuation and Earnings

Globus Medical, Inc. has a net margin of 28.31% compared to Intuitive Surgical, Inc.'s net margin of 15.47%. Intuitive Surgical, Inc.'s return on equity of 16.38% beat Globus Medical, Inc.'s return on equity of 10.08%.

Intuitive Surgical, Inc. has a consensus price target of $608.26, signalling upside risk potential of 3.76%. On the other hand Globus Medical, Inc. has an analysts' consensus of $106.40 which suggests that it could grow by 12.63%. Given that Globus Medical, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Globus Medical, Inc. is more attractive than Intuitive Surgical, Inc..

Intuitive Surgical, Inc. has a beta of 1.669, which suggesting that the stock is 66.867% more volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.426%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.

Intuitive Surgical, Inc. quarterly revenues are $2.5B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. Intuitive Surgical, Inc.'s net income of $709.2M is higher than Globus Medical, Inc.'s net income of $119M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 77.60x while Globus Medical, Inc.'s PE ratio is 30.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 22.18x versus 4.70x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 28.31% compared to Intuitive Surgical, Inc.'s net margin of 12.4%. Intuitive Surgical, Inc.'s return on equity of 16.38% beat Insulet Corp.'s return on equity of 18.92%.

Intuitive Surgical, Inc. has a consensus price target of $608.26, signalling upside risk potential of 3.76%. On the other hand Insulet Corp. has an analysts' consensus of $375.60 which suggests that it could grow by 29.95%. Given that Insulet Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Insulet Corp. is more attractive than Intuitive Surgical, Inc..

Intuitive Surgical, Inc. has a beta of 1.669, which suggesting that the stock is 66.867% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.400, suggesting its more volatile than the S&P 500 by 39.975%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Intuitive Surgical, Inc. quarterly revenues are $2.5B, which are larger than Insulet Corp. quarterly revenues of $706.3M. Intuitive Surgical, Inc.'s net income of $709.2M is higher than Insulet Corp.'s net income of $87.6M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 77.60x while Insulet Corp.'s PE ratio is 83.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 22.18x versus 8.30x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 28.31% compared to Intuitive Surgical, Inc.'s net margin of 14.18%. Intuitive Surgical, Inc.'s return on equity of 16.38% beat Stryker Corp.'s return on equity of 14.06%.

Intuitive Surgical, Inc. has a consensus price target of $608.26, signalling upside risk potential of 3.76%. On the other hand Stryker Corp. has an analysts' consensus of $427.40 which suggests that it could grow by 16.2%. Given that Stryker Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Stryker Corp. is more attractive than Intuitive Surgical, Inc..

Intuitive Surgical, Inc. has a beta of 1.669, which suggesting that the stock is 66.867% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 10.974%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.93% to investors and pays a quarterly dividend of $0.88 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intuitive Surgical, Inc. quarterly revenues are $2.5B, which are smaller than Stryker Corp. quarterly revenues of $6.1B. Intuitive Surgical, Inc.'s net income of $709.2M is lower than Stryker Corp.'s net income of $859M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 77.60x while Stryker Corp.'s PE ratio is 48.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 22.18x versus 5.82x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 28.31% compared to Intuitive Surgical, Inc.'s net margin of 17.41%. Intuitive Surgical, Inc.'s return on equity of 16.38% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Intuitive Surgical, Inc. has a consensus price target of $608.26, signalling upside risk potential of 3.76%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 25.48%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than Intuitive Surgical, Inc..

Intuitive Surgical, Inc. has a beta of 1.669, which suggesting that the stock is 66.867% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.728%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.31% to investors and pays a quarterly dividend of $0.22 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intuitive Surgical, Inc. quarterly revenues are $2.5B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Intuitive Surgical, Inc.'s net income of $709.2M is higher than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 77.60x while West Pharmaceutical Services, Inc.'s PE ratio is 40.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 22.18x versus 6.65x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.